Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Regulation of ErbB2 receptor status by the proteasomal DUB POH1.

PloS one | May 13, 2009

Understanding the factors, which control ErbB2 and EGF receptor (EGFR) status in cells is likely to inform future therapeutic approaches directed at these potent oncogenes. ErbB2 is resistant to stimulus-induced degradation and high levels of over-expression can inhibit EGF receptor down-regulation. We now show that for HeLa cells expressing similar numbers of EGFR and ErbB2, EGFR down-regulation is efficient and insensitive to reduction of ErbB2 levels. Deubiquitinating enzymes (DUBs) may extend protein half-lives by rescuing ubiquitinated substrates from proteasomal degradation or from ubiquitin-dependent lysosomal sorting. Using a siRNA library directed at the full complement of human DUBs, we identified POH1 (also known as Rpn11 or PSMD14), a component of the proteasome lid, as a critical DUB controlling the apparent ErbB2 levels. Moreover, the effects on ErbB2 levels can be reproduced by administration of proteasomal inhibitors such as epoxomicin used at maximally tolerated doses. However, the extent of this apparent loss and specificity for ErbB2 versus EGFR could not be accounted for by changes in transcription or degradation rate. Further investigation revealed that cell surface ErbB2 levels are only mildly affected by POH1 knock-down and that the apparent loss can at least partially be explained by the accumulation of higher molecular weight ubiquitinated forms of ErbB2 that are detectable with an extracellular but not intracellular domain directed antibody. We propose that POH1 may deubiquitinate ErbB2 and that this activity is not necessarily coupled to proteasomal degradation.

Pubmed ID: 19436748 RIS Download

Mesh terms: Catalysis | Cells, Cultured | Down-Regulation | Flow Cytometry | HeLa Cells | Humans | Proteasome Endopeptidase Complex | RNA, Small Interfering | Receptor, ErbB-2 | Trans-Activators | Ubiquitin

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Cancer Research UK

Cancer Research UK is the world''s leading charity dedicated to beating cancer through research. We''ve saved millions of lives with our groundbreaking work into preventing, diagnosing and treating cancer. People''s chances of surviving cancer have doubled in the last 40 years, and we''ve been at the heart of that progress. But more than one in three of us will still get cancer at some point. Our vital work, funded entirely by the public, will help ensure that millions more people survive. Our aim is to save lives from cancer. More people are beating cancer than ever before thanks to our work and your support. We work in the areas where we can make the most impact: * Research we support the work of over 4,000 scientists, doctors and nurses across the UK to investigate all aspects of cancer. * Information we work to prevent cancer and help people cope with its effects by providing information for cancer patients and their families, health professionals and the general public. * Influencing public policy we campaign to keep cancer at the top of the health agenda. Cancer Research UK is a registered charity in England and Wales (1089464) and in Scotland (SC041666). Registered as a company limited by guarantee in England & Wales No. 4325234.

tool

View all literature mentions